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and Alters Hematopoietic Support of Bone
Marrow Mesenchymal Stromal Cells
Marieke Goedhart,1,* Anne S. Cornelissen,1,* Carlijn Kuijk,1 Sulima Geerman,1
Marion Kleijer,1 Jaap D. van Buul,2 Stephan Huveneers,2,{ Marc H.G.P. Raaijmakers,3
Howard A. Young,4 Monika C. Wolkers,1 Carlijn Voermans,1,{ and Martijn A. Nolte1,{
Bone marrow (BM) mesenchymal stromal cells (MSCs) provide microenvironmental support to hematopoietic
stem and progenitor cells (HSPCs). Culture-expanded MSCs are interesting candidates for cellular therapies due to
their immunosuppressive and regenerative potential which can be further enhanced by pretreatment with
interferon-gamma (IFN-g). However, it remains unknown whether IFN-g can also influence hematopoietic support
by BM-MSCs. In this study, we elucidate the impact of IFN-g on the hematopoietic support of BM-MSCs. We
found that IFN-g increases expression of interleukin (IL)-6 and stem cell factor by human BM-MSCs. IFN-g-
treated BM-MSCs drive HSPCs toward myeloid commitment in vitro, but impair subsequent differentiation of
HSPC. Moreover, IFN-g-ARE-Del mice with increased IFN-g production specifically lose their BM-MSCs, which
correlates with a loss of hematopoietic stem cells’ quiescence. Although IFN-g treatment enhances the immu-
nomodulatory function of MSCs in a clinical setting, we conclude that IFN-g negatively affects maintenance of
BM-MSCs and their hematopoietic support in vitro and in vivo.
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Introduction
Maintenance of hematopoietic stem cells (HSCs) iskey for life-long blood cell formation, which requires
an appropriate balance between HSC quiescence, self-renewal,
and differentiation. Therefore, HSCs reside in vascular niches
in the bone marrow (BM) that consist of endothelial cells and
perivascular mesenchymal stromal cells (MSCs)[1]. These
cells promote HSC maintenance through secretion of hema-
topoietic support factors, such as stem cell factor (SCF) and
CXCL12, which stimulate survival and attract HSCs to the
niche, respectively. Conditional deletion of these factors
from vascular niche cells results in a loss of quiescent HSCs
and long-term repopulating activity [2,3].
MSCs are present at very low frequencies in the BM and
BM aspirates [4,5]. To obtain sufficient cell numbers for
clinical applications, MSCs must be ex vivo expanded. Con-
gruent to their role as supporting stromal cells in the vascular
niche, expanded BM-MSCs also provide hematopoietic sup-
port to HSCs ex vivo [6]. MSCs also have the potential to
generate other mesenchymal cell types, such as osteoblasts,
chondrocytes, and adipocytes [5], indicating that they also
may play a critical role in tissue regeneration. Indeed, culture-
expanded BM-MSCs can engraft in osteogenesis imperfecta
patients and attenuate the disease by forming osteoblasts that
stimulate dense bone formation [7]. Furthermore, culture-
expanded BM-MSCs exhibit immunoregulatory properties
toward numerous innate and adaptive effector cells [8].
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BM-MSCs are thus attractive candidates for cellular therapy
after HSC transplantation to promote rapid hematopoietic
recovery and reduce the incidence and severity of graft-
versus-host disease (GvHD) [9,10].
Expansion of MSCs ex vivo enables their modification with
external factors to optimize them for cellular therapy. Recently,
there has been considerable interest in the effect of cytokines
on the therapeutic efficacy of culture-expanded BM-MSCs.
Many studies support the notion that the immunosuppres-
sive function of BM-MSCs is strongly enhanced by exposure
to the proinflammatory cytokine interferon-gamma (IFN-g)
(reviewed in Ref. [11]). Stimulation of BM-MSCs with IFN-g
before their administration in mouse models of acute GvHD is
associated with reduced T cell proliferation and prolonged
survival [12,13]. Other studies have suggested that preactiva-
tion with IFN-g enhances the migratory capacities and repar-
ative properties of BM-MSCs [14,15], which is desirable, as
MSCs have very limited migratory capacities (reviewed in Ref.
[16,17]). Moreover, IFN-g stimulation before cryopreservation
can enhance MSC fitness after thawing [18]. Thus, IFN-g can
potentiate the immunomodulatory and tissue regenerative ca-
pacity of MSCs, and thereby generate a potent cell population
for application in various clinical conditions (reviewed in Ref.
[19]). To date, however, little attention has been devoted to the
effect of IFN-g on hematopoietic support by BM-MSCs.
We and others have reported that IFN-g can have a det-
rimental effect on the maintenance and self-renewal of HSCs
during inflammatory conditions [20–22], but the impact on
BM-MSCs is unclear. One possibility is that MSCs are acti-
vated by IFN-g and thereby enhance their hematopoietic
supportive capacity during inflammatory stress. Alternatively,
a negative effect of IFN-g on the hematopoietic support
function of MSCs can be one of the mechanisms underlying
hematopoietic exhaustion observed in HSCs during inflam-
mation [23]. Considering the essential survival and quies-
cence enforcing signals for HSCs provided by MSCs in vivo,
it is important to determine whether the supportive function
of MSCs is influenced by a proinflammatory environment. In
addition, if IFN-g also enhances the ability of culture-
expanded BM-MSCs to support the hematopoietic function of
HSCs, this may further expand the clinical conditions for
which BM-MSCs could be applied as cellular therapy.
The objective of the present study is therefore to examine
the impact of IFN-g on hematopoietic support by BM-MSCs.
We demonstrate that, in contrast to other functional charac-
teristics, the hematopoietic support function of BM-MSCs
does not benefit from pretreatment with IFN-g. In fact, we
show that IFN-g impairs maintenance of BM-MSCs in vitro
and in vivo, which has detrimental effects on HSC function.
Materials and Methods
Human BM-MSC culture
BM samples were obtained from patients (age range 18–70
years) undergoing median sternotomy for cardiac surgery,
after informed consent and approval of the medical Ethics
Review Board of the AMC (MEC:04/042#04.17.370). Briefly,
BM mononuclear cells were isolated by density gradient
centrifugation (Ficoll-Paque) and seeded in T80 tissue culture
flasks (2.5 - 3.75 · 105 cells/cm2) in DMEM GlutaMAX (low
glucose) supplemented with 10% fetal calf serum (FCS) and
1% penicillin–streptomycin. After 48 h, nonadherent cells
were removed. When reaching 80%–90% confluency (3–4
weeks for each passage), MSCs were trypsinized with TrypLE
(Gibco) and further cultured. For the experiments, MSCs up
until passage 2 were used.
IFN-c stimulation
IFN-g stimulation of MSC was initiated 2 weeks after the
initial isolation. In brief, normal culture medium was re-
moved and culture medium with 10 ng/mL recombinant
human IFN-g (Imukin, Boehringer Ingelheim), was added.
Culture medium of IFN-g-stimulated MSC, now referred to
as MSC-g, was refreshed once a week and experiments were
initiated 3–4 days after a medium change.
Human BM-MSC and hematopoietic stem
and progenitor cell coculture
Cocultures of MSCs and hematopoietic stem and pro-
genitor cells (HSPCs) were performed as previously de-
scribed [24]; graphical summary of the experimental set-up
is shown in Supplementary Fig. S1A (Supplementary Data
are available online at www.liebertpub.com/scd). In brief,
MSC and MSC-g were harvested, IFN-g was washed away
and cells were subsequently seeded in 48-well plates at the
density of 40,000 cells/well (equal cell numbers for MSC
and MSC-g). Cord blood (CB) was collected according to
the guidelines of Eurocord Nederland and CD34+ cells were
isolated as previously described [25]. Ten thousand CD34+
cells were added onto the stromal layers and cocultured in
MyeloCult (H5100; Stem Cell Technologies) for 7 days at
37C and 5% CO2. During the coculture, no IFN-g was
present. On day 7, the complete coculture was trypsinized
with TrypLE (Gibco) and harvested. Total hematopoietic
cells were characterized for surface expression of various
markers using an LSRII flow cytometer (BD Biosciences)
and cells were counted with Cyto-Cal fluorescent beads
(Thermo Scientific, Fremont, CA). The gating strategy for
the surface marker expression analysis is depicted in Sup-
plementary Fig. S1B. MSCs, present in the coculture, were
excluded from the hematopoietic surface marker expression
on the flow cytometer based on CD73 expression. On av-
erage, 5,000 gated events (HSPC) were acquired per sample.
Cell counting was performed using Cyto-Cal fluorescent
beads (1 · 106/mL) that were added to the cell suspension.
Cell concentration was calculated with the following for-
mula: (A/B) · (C/D) in which A = number of recorded cell
events, B = number of recorded bead events, C = assigned
bead count (beads/50 mL), and D = volume of sample (mL).
Human hematopoietic colony formation
For hematopoietic colony formation assays, the non-
adherent fraction of hematopoietic cells was harvested after
7 days of coculturing with MSCs and a volume of 500mL
was plated in MethoCult (H4434; Stem Cell Technologies)
in duplicates in 24-well plates. Cultures were scored for the
presence of hematopoietic colonies (CFU-granulocyte,
erythrocyte, monocyte, megakaryocyte [GEMM], colony-
forming unit granulocyte-monocyte [CFU-GM] or burst-
forming unit-erythroid [BFU-E]) in duplo after 14 days of
incubation at 37C and 5% CO2.
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Mice
For murine experiments, IFN-g AU-rich elements (ARE)-
Del mice and wild-type (WT) mice were used [26]. Mice
were maintained on a C57BL/6 background in the animal
facilities of the Netherlands Cancer Institute (Amsterdam,
The Netherlands) in specific pathogen-free conditions. Mice
were given standard chow and acidified drinking water ad
libitum. Femurs and tibiae of Nestin-GFP mice [27] were
used for confirmation of our murine MSC gating strategy.
All animal experiments were approved by the Experimental
Animal Committee of the Netherlands Cancer Institute,
according to institutional and national guidelines.
Murine BM cell isolation
Murine BM cells were obtained by mildly crushing femurs
and tibiae with a mortar and pestle. For stromal cell isola-
tions, bones were digested with Liberase TM grade and
DNAse I (Roche Diagnostics) for 30 min at 37C. All single-
cell suspensions were filtered through a 70-mm cell strainer.
Murine long-term-HSC cultures
For 7-day HSC cultures, 500 HSCs (Lin- c-Kit-
Sca-1+CD48-CD150+) were sorted and cultured in 96-well
plates in X-VIVO 15 medium (Lonza) with 2 ng/mL
thrombopoietin and SCF and 5 ng/mL IL-3, IL-6, and Flt3-
L. Cells were cultured at 37C in a humidified incubator at
5% CO2. All cytokines were obtained from PeproTech.
Flow cytometry and cell sorting
FACSCanto II (BD Biosciences), LSR II (BD Bio-
sciences), and FACSAria (BD Biosciences) were used for
flow cytometric analysis and cell sorting. Human MSCs
were stained with Near IR Live–Dead marker (Life Tech-
nologies), CD45 (clone HI30), CD34 (clone 8G12), CD73
(clone AD2), CD90 (clone 5E10), CD105 (clone 266),
human leukocyte antigen ABC (HLA-ABC) (clone G46–2.6),
and human leukocyte antigen DR (HLA-DR) (clone G46-6;
all from BD Biosciences). On average, the purity of cells that
fulfill the MSC criteria (CD45-, CD34-, CD73+, CD90+, and
CD105+) was 96%. Human HSPCs were stained with Near
IR Live–Dead marker (Life Technologies), CD13 (clone
WM15), CD14 (clone M5E2), CD33 (clone WM53) CD34
(clone 8G12), CD45 (clone HI30), CD235a (clone GA-R2; all
from BD biosciences), CD36 (clone M1613; Sanquin), and
CD41 (clone 5B12; Dako). For flow cytometric analysis and
cell sorting of murine MSC, whole digested BM was enriched
for stromal cells by negative depletion of hematopoietic cells
using CD45 microbeads (Miltenyi Biotec), and cells were
stained for CD45.2 (clone 104), Ter119 (clone TER-119),
CD31 (clone 390), PDGFRa (clone APA5), andCD51 (clone
RMV-7; all from eBioscience). For flow cytometric analysis
of murine HSC, whole BM was stained for lineage markers,
(CD4 [clone GK1.5], CD8 [clone 53-6.7], B220 [clone RA3-
6B2], CD11b [clone M1/70], Gr-1 [clone RB6-8C5], and
Ter119 [clone TER-119]); Sca-1 (clone D7), c-kit (clone
2B8), CD48 (clone HM48-1), and CD150 (clone TC15-
12F12.2; all from eBioscience). Intracellular staining of Ki-67
or isotype control (BD Biosciences) was performed after
fixation with the Foxp3/Transcription Factor Staining buffer
set (eBioscience). For intracellular staining of IFN-g in T cell
and NK cell subsets, whole BM was stained with biotin-
labeled antibodies against B220 (clone RA3-6B2), CD11b
(clone M1/70), Gr-1 (clone RB6-8C5), and Ter119 (clone
TER-119; all from eBioscience), and enriched for T cells NK
cells by negative depletion of biotin-labeled cells using
streptavidin microbeads (Miltenyi Biotec). Subsequently, the
enriched cell suspension was cultured for 4 h in IMDM (Lonza)
supplemented with 10% FCS and 0.1% 2-Mercaptoethanol
(Sigma) in the presence of Brefeldin A (eBioscience). Subsets
of T cells, NK cells, and NK T cells were identified with an-
tibodies against CD3 (clone 17A2), CD4 (clone GK1.5), CD8
(clone 53-6.7), CD44 (clone IM7), CD62L (clone MEL-14),
and NK1.1 (clone PK136; all from eBioscience). Intracellular
staining for IFN-g protein was performed after fixation with the
Cytofix/Cytoperm Solution Kit (BD Biosciences). Before
sorting murine long-term HSC (LT-HSC), whole BM was
stained with the biotinylated lineage markers and enriched for
progenitors by negative depletion of lineage cells using strep-
tavidin microbeads (Miltenyi Biotec).
Quantitative real-time polymerase chain reaction
For human samples, total RNA was extracted with the
RNeasy Mini Kit according to the manufacturer’s instruc-
tions (Qiagen). First-strand cDNA synthesis was performed
on the full volume of RNA solution, without measuring the
quantity of RNA, using M-MLV reverse transcriptase and
random hexamer primers (both from Invitrogen). For murine
samples, RNA was extracted using TRIzol (Invitrogen) and
complementary DNA was made with iScript Reverse
Transcription Supermix for quantitative real-time polymer-
ase chain reaction reactions (RT-qPCR; Bio-Rad). RT-
qPCRs were performed on a StepOnePlus (Applied Bio-
systems) using TaqMan or SYBR Green dye for detection
(both from Applied Biosystems). Forty cycles were used for
amplification. Data were normalized using ABL1 (human)
and Cyclophilin (murine) as reference genes using the
double delta Ct method: 2-(DCt sample -DCt reference gene). Pri-
mer sequences and amplicon sizes are listed in Table 1.
Statistics
Statistical analyses were performed with GraphPad Prism 7.
Mean values plus or minus standard deviation or standard error
of the mean are shown. *P < 0.05; **P < 0.01; ***P < 0.001.
Results
IFN-c exposure alters the expression of
hematopoietic cytokines secreted by MSCs
We first determined the impact of IFN-g on the phenotype
and function of human MSC. MSCs were continuously ex-
posed to IFN-g in culture for 1–2 passages. Culturing in the
presence of IFN-g resulted in a reduced expansion of MSC
(Supplementary Fig. S2a). As expected for cells exposed to
IFN-g [28], HLA-ABC, and HLA-DR expression was in-
creased (Fig. 1a). Moreover, phenotypic expression of the
classical MSC markers (>95% according to the ISCT cri-
teria [29]) CD73, CD90, and CD105 remained stable during
the course of the experiment. This is important as others
have shown that IFN-g can alter multilineage differentiation
of MSCs with a skewing toward osteogenesis and a reduc-
tion in adipogenesis [30,31].
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MSCs produce a plethora of hematopoietic supportive
factors, including IL-6, SCF, and CXCL12, and we examined
whether IFN-g altered the expression of these supporting
mediators by MSC. As a positive control, we could demon-
strate that IFN-g increased the expression of indoleamine 2,3
dioxygenase, a direct target gene of IFN-g [32]. Interestingly,
while the levels of CXCL12 mRNA were unaffected by IFN-g
exposure, we observed a significant increase in IL6 mRNA
expression, a factor that activates myelopoiesis in response to
infection and chronic inflammation [33–35]. Furthermore, the
expression of SCF, which is involved in HSC maintenance [2],
was also increased (Fig. 1b). Altogether, these data show
that IFN-g exposure enhances expression of hematopoietic
cytokines, while stably maintaining the expression of classi-
cal MSC markers and CXCL12.
IFN-c exposure alters the hematopoietic support
function of MSCs
To examine the impact of IFN-g on the hematopoietic
support function of MSCs, we used an in vitro coculture
system of human BM-MSCs and umbilical CB CD34+
HSPCs, in which the MSCs strongly support both the main-
tenance and the outgrowth of HSPCs [24,36,37]. Viable
MSCs, expanded without or with IFN-g (MSC vs. MSC-g),
were cocultured with CB CD34+ HSPCs for 7 days (Experi-
mental set-up shown in Supplementary Fig. S1a; representa-
tive images in Supplementary Fig. S2b). After the coculture,
all cells were harvested and total hematopoietic cells were
counted. To validate that the effects of IFN-g stimulation of
MSCs lasts for 7 days, MSCs were phenotypically analyzed
before and after the coculture. Upregulation of HLA-ABC and
HLA-DR was still present at the end of the coculture, sug-
gesting that the effect of IFN-g stimulation is maintained
during the coculture (Supplementary Fig. S3).
In contrast to the increase in hematopoietic cytokine pro-
duction, we observed no significant differences in total he-
matopoietic cell counts between MSC and MSC-g conditions
(Fig. 1c). Similar results were obtained when MSCs were
cultured with IFN-g for 40–48 h, a timeframe that has been
reported to enhance immunomodulatory, migratory, and re-
generative capacities of MSCs for clinical applications
(Supplementary Fig. S4a) [11,14,15]. This suggests that both
long- and short-term IFN-g stimulation of MSCs do not lead
to a gain of function in hematopoietic support. To study
whether MSC-g could boost the clonogenic capacity of
HSPCs, we performed hematopoietic colony assays on cells
derived from a 1-week coculture of HSPCs and MSCs. After
2 weeks, CFU-GM, BFU-E, and GEMM colonies were
counted. No significant differences in progenitor supporting
capacity were observed between MSC and MSC-g, neither in
the number nor the type of colonies (Fig. 1d). Similar results
were obtained when MSCs were stimulated with IFN-g only
for 40–48 h (Supplementary Fig. S4b). These data indicate
that MSC-g could still support the maintenance of functional
hematopoietic progenitor cells. This was in accordance with
flow cytometric analysis on HSPCs after 7 days of co-
culturing, as we found that the number of myeloid progenitor
cells (CD34+/CD13/33+ cells) was maintained and even
slightly increased (P = 0.0439) (Fig. 1e). However, the num-
ber of differentiated myeloid cells (CD14+ and CD36+ cells)
was strongly reduced when HSPCs were grown on MSC-g
(P = 0.0014 and 0.0067, respectively) (Fig. 1e). This indicates
that IFN-g treatment of MSCs supports myeloid commitment
of HSPCs, but impairs subsequent maturation toward mono-
cytes/macrophages. Hematopoietic cell viability after the co-
culture was similar between MSC and MSC-g conditions
(data not shown). Moreover, CD41 (megakaryocyte maker)
and CD235a (red cell lineage marker) expression on HSPC
was not altered (Supplementary Fig. S5), suggesting that there
is no lineage skewing upon coculturing with MSC-g.
BM-MSCs are reduced in vivo after IFN-c exposure
These data demonstrate that IFN-g does not boost the he-
matopoietic support function of in vitro-expanded MSCs,
Table 1. Primer Sequences
Gene Primer sequence Amplicon size (bp)
Human ABL1 (forward) 5¢ TGG AGA TAA CAC TCT AAG CAT AAC TAA AGG T 3¢ 124
Human ABL1 (reverse) 5¢ GAT GTA GTT GCT TGG GAC CCA 3¢
Human ABL1 (probe) 5¢ CCA TTT TTG GTT TGG GCT TCA CAC CAT T 3¢
76Human CXCL12 (forward) 5¢ TCT CAA AAT TCT CAA CAC TCC AAA CT 3¢
Human CXCL12 (reverse) 5¢ GCA CAC TTG TCT GTT GTT GTT CTT C 3¢
193Human IL6 (forward) 5¢ TCT CCA CAA GCG CCT TCG 3¢
Human IL6 (reverse) 5¢ CTC AGG GCT GAG ATG CCG 3¢
81Human IDO1 (forward) 5¢ ACC ATA TTG ATG AAG AAG TGG GC 3¢
Human IDO1 (reverse) 5¢ TGA ACA TCC AGT CAT TAT AAA AAT CAG G 3¢
85Human SCF (forward) 5¢ AGC GCT GCC TTT CCT TAT GA 3¢
Human SCF (reverse) 5¢ GA CGA GAG GAT TAA ATA GGA GCA 3¢
101Mouse Cxcl12 (forward) 5¢ CAG AGC CAA CGT CAA GCA TCT 3¢
Mouse Cxcl12 (reverse) 5¢ GGT CAA TGC ACA CTT GTC TGT TGT 3¢
109Mouse Scf (forward) 5¢ AAG GAG ATC TGC GGG AAT CC 3¢
Mouse Scf (reverse) 5¢ CCA TCC CGG CGA CAT AGT T 3¢
125Mouse Nes (forward) 5¢ GCT GGA ACA GAG ATT GGA AGG 3¢
Mouse Nes (reverse) 5¢ CCA GGA TCT GAG CGA TCT GAC 3¢
112Mouse Ppia (forward) 5¢ ACC CAT CAA ACC ATT CCT TCT GTA 3¢
Mouse Ppia (reverse) 5¢ TGA GGA AAA TAT GGA ACC CAA AGA 3¢
Primer sequences and amplicon sizes for the human and murine genes analyzed by RT-qPCR.
SCF, stem cell factor; RT-qPCR, quantitative real-time polymerase chain reaction.
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FIG. 1. IFN-g alters hematopoietic support by MSCs. (A) Phenotypical flow cytometric analysis of unstimulated (MSC)
or IFN-g-stimulated MSCs (MSC-g). MSCs were negative for CD34 and CD45 and positive for CD73, CD90, and CD105. Upon
IFN-g stimulation HLA-ABC and HLA-DR were upregulated. Filled histograms represent isotype control. Flow cytometric
analyses were performed for all MSC donors used in the coculture experiments (n = 6). Representative example. (B) mRNA
expression of IL-6, SCF, CXCL12, and IDO in MSC and MSC-g was analyzed by QPCR. ABL1 was used as a housekeeping gene
to normalize and determine the expression levels (n = 5–6). (C) Total hematopoietic cell counts (absolute) after 7 days of coculturing
MSC or MSC-gwith HSPCs (n = 6). (D) After 7 days of coculturing MSC or MSC-gwith HSPCs, a volume of 500mL was seeded in
methylcellulose medium to examine the total supporting capacity of the culture. Colony-forming precursors were counted after
14 days of culturing. Bars represent the average total (mean–SD; n = 6). (E) Flow cytometric analysis of hematopoietic cells after
7 days of coculturing MSC or MSC-g with HSPCs. Presence of CD34+-CD13/33+ (myeloid progenitors), CD14+, and CD36+
(monocyte) hematopoietic cells was determined (n = 6). (F). Expansion of MSC and MSC-g cultured in M199 media supplemented
with 10% FCS, 1% penicillin–streptomycin, 20mg/mL ECGF, and 8 IU/mL heparin (mean–SD; n = 5; paired t-test). In all
experiments MSC-gwere continuously cultured in medium containing 10 ng/mL recombinant human IFN-g. For each n-number, a
unique MSC donor and a unique cord blood donor were used. *P < 0.05; **P < 0.01 paired t-test. CFU, colony-forming unit; GM,
granulocyte–monocyte; GEMM, granulocyte–erythrocyte–monocyte–megakaryocyte; BFU-E, burst-forming unit-erythroid;
MSC, mesenchymal stromal cell; HSPC, hematopoietic stem and progenitor cell; IFN-g, interferon-gamma; SCF, stem cell factor;
SD, standard deviation; IDO, indoleamine 2,3 dioxygenase; HLA-ABC, human leukocyte antigen ABC; HLA-DR, human
leukocyte antigen DR; QPCR, quantitative real-time PCR; FCS, fetal calf serum; ECGF, endothelial cell growth factor.
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which is important for the exploration of the clinical potential
and applicability of IFN-g-stimulated MSCs. However, it could
be that the in vivo impact of IFN-g on the HSC-supporting
function of MSCs in the BM niches is quite different. As the
biology and function of IFN-g is evolutionarily highly con-
served between man and mouse, we addressed this question in
a mouse model, in which IFN-g expression is moderately in-
creased, without inducing an infection. We made use of a
transgenic mouse model with a 162 nt deletion of the ARE in
the 3¢ untranslated region of the IFN-g gene. This deletion
drives continuous IFN-g production, as evidenced by chronic
low levels of IFN-g in serum (10–30 pg/mL) [26]. IFN-g
production in the BM was also increased, as evidenced by a
higher percentage of IFN-g-producing NK cells, NKT cells,
and T cell subsets compared in ARE-Del mice compared with
WT controls (Fig. 2a, b). Importantly, chronic exposure to
IFN-g did not alter total BM cell numbers in ARE-Del
compared with WT controls (Fig. 2c).
Murine BM-MSCs were defined as CD45-Ter119-CD31-
PDGFRa+CD51+ cells (Fig. 2d) [38]. We confirmed that
these cells produce the vast majority of the hematopoietic
support factors CXCL12 and SCF in the BM, and that they
are positive for the commonly used MSC-marker Nestin
(Supplementary Fig. S6a, b) [38,39]. When assessing the
impact of chronic in vivo exposure of IFN-g on BM stromal
cells, we found that particularly BM-MSCs were signifi-
cantly reduced in the BM stromal compartment of ARE-Del
mice (Fig. 2e; Supplementary Fig. S7a), whereas other
stromal subsets, including endothelial cells (Supplementary
Fig. S7b), were not significantly affected.
When analyzing the functional characteristics of the re-
maining BM-MSCs of ARE-Del mice, we found that in-
creased exposure to IFN-g did not affect the expression of
CXCL12 and SCF on a per cell basis (Fig. 2f), suggesting
that the persisting MSCs were still functionally intact. Im-
portantly, analysis of young, 3-week-old mice, which still
lack IFN-g-producing cells in the BM (data not shown),
revealed that MSCs do develop normally in ARE-Del mice,
although rapidly decline when the mice age and IFN-g-
producing cells accumulate in the BM (Fig. 2g). In con-
clusion, using this sterile inflammation model, we demon-
strate that increased IFN-g production induces loss of BM-
MSCs in vivo. This discovery is in line with previous studies
[32,40], as well as our own observations (Fig. 1f; Supple-
mentary Fig. S2a) that IFN-g has a detrimental effect on the
proliferative capacity of cultured human MSCs.
IFN-c-mediated loss of BM-MSCs coincides
with loss of HSC quiescence
As MSCs contribute to the maintenance and quiescence
of HSCs [3,39,41], we examined to what extent the IFN-g-
mediated loss of MSCs affected the composition of the
hematopoietic progenitor compartment in ARE-Del mice.
We identified HSPCs by classifying the HSC-containing
Lineage- Sca-1+ c-kit+ (LSK) population and further sub-
dividing HSCs and progenitors using the SLAM family re-
ceptors CD150 and CD48 (Fig. 3a) [42]. Within the LSK
population of ARE-Del mice, we observed a skewed distri-
bution of CD150+CD48- LT-HSC, CD150+CD48+ short-term
HSC (ST-HSC), and CD150-CD48+ multipotent progenitors
(MPP): LT-HSCs were significantly underrepresented in the
LSK fraction of ARE-Del mice compared with WT controls,
but this did not result in a significant decline of total LT-HSC
numbers (Fig. 3b, c). However, Ki-67 staining revealed that
LT-HSCs in ARE-Del mice exhibit a loss of quiescence: only
35% of LT-HSC in ARE-Del mice were quiescent compared
with 70% in WT controls (Fig. 3d, e). Loss of quiescence in
LT-HSC did not lead to increased self-renewal, as we did not
observe increased numbers of LT-HSC in ARE-Del mice.
Instead, it is more likely that loss of quiescence in LT-HSCs
enhanced their subsequent differentiation toward more com-
mitted progenitors, which was corroborated by higher abso-
lute numbers of ST-HSC and MPP in ARE-Del mice
compared with WT controls (Fig. 3c).
To further investigate the functional capacities of ARE-Del
LT-HSC, we sorted LT-HSC from WT and ARE-Del mice
and performed an in vitro HSC culture assay. We previously
showed that phenotypical LT-HSCs remain functionally in-
tact in this assay and that they are capable of long-term,
multilineage reconstitution [22]. We observed after 7 days
that the absolute number of phenotypical LT-HSC was sig-
nificantly decreased in ARE-Del compared with WT cultures
(Fig. 3f). This loss of LT-HSC maintenance coincided with
increased differentiation toward MPPs, myeloid progenitors,
and differentiated myeloid cells, indicating that LT-HSC in
ARE-Del mice lost their ability to self-renew and rapidly
differentiated toward the myeloid lineage. We thus found
decreased quiescence in LT-HSC from adult ARE-Del mice,
which resulted in decreased maintenance of phenotypical LT-
HSC upon in vitro culture.
Finally, we anticipated that the LT-HSC pool would be-
come exhausted upon aging and that the LT-HSCs could not
be maintained in old ARE-Del mice. Indeed, when exam-
ining the BM of 1-year-old mice, we found that the number
of BM-MSCs was still significantly reduced in ARE-Del
compared with WT control mice (Fig. 3g), which coincided
with a significant reduction in the absolute number of LT-
HSCs (Fig. 3h). These findings indicate that IFN-g-mediated
loss of BM-MSCs coincides with a decrease in HSC qui-
escence and a subsequent exhaustion of the LT-HSC pool
upon aging. Thus, we conclude from these data that in vivo
exposure of BM-MSC to IFN-g has a detrimental effect on
MSC maintenance and is therefore destructive for long-term
support of quiescent HSCs.
Discussion
IFN-g potentiates the immunomodulatory and tissue re-
generative capacity of MSCs, and thereby generates a potent
MSC population for application in various clinical condi-
tions (reviewed in Ref. [19]). However, the effect of IFN-g
on hematopoietic support of MSCs has thus far not been
properly addressed. We show here that IFN-g impaired the
ex vivo maintenance of human BM-MSCs, and did not
further enhance their hematopoietic support capacity, but
rather inhibited myeloid differentiation. The lack of in-
creased hematopoietic support by MSC-g in our in vitro
culture assays, despite their increased expression of SCF,
could be due to the fact that cultured BM-MSC may already
produce sufficient amounts of SCF for HSPC maintenance,
with no additional effect of increased levels of SCF. In
addition, the myeloid skewing that is expected upon upre-
gulation of IL-6 [34] may be counteracted by potential other
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FIG. 2. BM-MSCs are reduced in vivo after IFN-g exposure. (A) Flow cytometric analysis and (B) quantification of IFN-g
production by BM T cells and NK cells from ARE-Del mice and WT controls. CD4+ and CD8+ T cells were defined as
CD3+CD4+CD8- and CD3+CD4-CD8+, respectively. CM = central memory (CD44+CD62L+). EM = effector memory
(CD44+CD62 L-). NK cells were defined as CD3-CD56+ and NKT cells were CD3+CD56+. Cells were incubated for 4 h without
any stimulus in the presence of Brefeldin A (mean–SD; n = 2–3). (C) Absolute number of total BM cells and (E) relative numbers
of BM stromal cell subsets and BM-MSCs in ARE-Del mice and WT controls (mean–SEM; n = 5). (D) Gating strategy for murine
BM MSCs (F) CXCL12 and SCF expression by sorted BM-MSC, normalized to Cyclophilin (mean–SEM; n = 5). (G) Percentage
of BM-MSCs in total BM cells of ARE-Del mice and WT controls between 3–30 weeks of age (mean–SEM; n = 3–5). *P < 0.05;
***P < 0.001 unpaired t-test. BM, bone marrow; WT, wild type; SEM, standard error of the mean; ARE, AU-rich elements.
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factors produced by MSC-y that inhibit myeloid skewing.
The difference found on myeloid progenitors assessed by
flow cytometry versus colony assays (Fig. 1E, D) probably
relates to the fact that only a subset of CD34+ cells is able to
give rise to colonies. It is most likely that the small increase
in HSPCs remaining at the end of the coculture is of a subset
that does not have significant colony-forming potential.
A recent study by Yang et al. claimed that IFN-g induces
senescence-like characteristics in murine MSC, which could
explain our findings that MSC maintenance is impaired
upon exposure to IFN-g [43]. In contrast, Chinnadurai et al.,
showed that prelicensing with IFN-g can correct some of the
senescence-associated characteristics of cultured human
MSC [44]. Thus, the exact mechanism by which IFN-g in-
fluences BM-MSCs is still under debate and arguably de-
pends greatly on the duration of the exposure. Prelicensing
with a short exposure of IFN-g enhances immunomodula-
tory capacities of cultured human MSC, and may therefore
be an attractive strategy for clinical application in inflam-
matory conditions (reviewed in Ref. [11]), especially be-
cause it has recently been suggested that the clinical risk of
infusing MSCg is not greater than the risk of infusing
nontreated MSCs [45]. It has also been reported that IFN-g
exposure of MSCs can mediate a shift from adipogenesis
toward osteoblastogenesis both in vitro and in vivo [30],
which may be beneficial for clinical application of cultured
human MSC in bone degenerative disorder. However, our
data argue against using longer IFN-g exposure of cultured
MSC destined for clinical application, as it negatively af-
fects their maintenance. In addition, our data do not support
a positive role for IFN-g in the hematopoietic support of
BM-MSC, and rather argue against using IFN-g-stimulated
MSCs for hematopoietic support in a clinical setting. A de-
finitive answer on this matter may be provided by experi-
ments, where BM-MSCs cultured in the presence or absence
of IFN-g are infused during a murine BM transplantation, and
engraftment of HSCs and hematopoietic reconstitution are
subsequently evaluated.
In addition to our findings that IFN-g does not boost the
hematopoietic support function of in vitro-expanded MSCs,
we identified a negative role for IFN-g on MSC in vivo in
the BM niche. Chronic exposure to IFN-g in mice resulted
in strongly reduced numbers of BM-MSCs, which corre-
lated with a concomitant loss of quiescent HSC. Although
HSCs and downstream progenitors can also directly re-
spond to high levels of IFN-g (reviewed in Ref. [23]), we
found no upregulation of the interferon-sensitive molecule
Sca-1 on HSPCs in ARE-Del mice (Fig. 3a; Supplementary
Fig. S8), in contrast to other models, in which higher levels
of IFN-g are produced [22]. Therefore, it is highly unlikely
that the observed HSC phenotype in the ARE-Del mice is
due to a direct effect of IFN-g. In support of this, also
acute production of IFN-g by adoptively transferred acti-
vated T cells, which does induce Sca-1 upregulation on
most BM cells, is not sufficient to affect HSC numbers
[34]. Moreover, we previously showed that direct IFN-g
exposure itself does not affect HSC quiescence [22]. Al-
together, these arguments thus imply that the observed loss
in HSC quiescence in ARE-Del mice is due to the detri-
mental effect of IFN-g on the HSC niche. This is supported
by recent work from O’Hagan-Wong et al., in which aging
and DNA damage in niche cells is coupled to loss of HSC
quiescence [46]. The concept that stress-induced changes
in stromal cells can affect the hematopoietic process has
also been recently proposed by Zambetti et al., who found
that perturbation of MSCs in a preleukemic mouse model
induces genotoxic stress in HSPCs and can predict disease
evolution in human preleukemia disorders [47]. Another
form of stress-induced changes in stromal cells has been
reported by Abbuehl et al., who show that MSCs are se-
verely impaired following upon preconditioning irradiation
for HSCT, which limits the reconstitution of donor-derived
HSC [48]. In addition, Schurch et al. have reported that IL-6
production by BM stromal cells upon inflammation can in-
duce a myeloid bias in hematopoiesis and thus increase
myeloid output of the BM [34]. We previously showed that
chronic IFN-g production contributes to the development of
acquired aplastic anemia (AAA) and we suggested that
nonhematopoietic cells could be involved in driving the loss
of HSC [49]. This is corroborated by our current findings
that IFN-g-mediated depletion of BM-MSCs in IFN-g ARE-
Del mice coincides with reduced quiescence of LT-HSC,
increased differentiation toward more committed progenitor
cells, and exhaustion of the LT-HSC pool upon aging.
Our definition of murine BM-MSCs as CD45-Ter119-
CD31-PDGFRa+CD51+ cells encompasses a population
with high expression of CXCL12. Although we did not
observe reduced CXCL12 expression by human MSC-g nor
BM-MSCs from ARE-Del mice, the decrease in total BM-
MSC numbers leads to a reduction in CXCL12-producing
HSC niches. When measuring the total amount of CXCL12
protein in BM supernatant, we could not find a significant
difference between WT and ARE-Del mice (data not
shown), though this could be due to the fact that the number
of CXCL12-producing cells in the BM is much higher than
the number of HSC-supporting niches, as endothelial cells
and stromal cells other than MSCs can also produce this
chemokine. Studies by Ding and Morrison and Tzeng et al.
showed that conditional deletion of CXCL12 only from Prx1+
and Osx+ stromal precursor cells results in loss of HSC qui-
escence [41,50], which is consistent with our findings. Ad-
ditionally, loss of HSC quiescence upon CXCL12 deletion
leads to an expansion of the hematopoietic progenitor pool
[41,50]. Thus, a reduction in the number of CXCL12+ ni-
ches in the BM could explain the loss of quiescent LT-HSC
and increased differentiation to progenitors in ARE-Del
mice. Our results are therefore congruent with the findings
that the production of CXCL12 by BM-MSCs in the vas-
cular BM niche is essential for maintaining the balance
between quiescence and proliferation in HSCs [3].
By combining results on human BM-MSCs as well as
mouse BM-MSCs, in vivo and in vitro, we provide clinical
relevance as well as biological significance. An important
implication of our results is that prestimulation of BM-
MSCs with IFN-g for clinical purposes is not favorable for
hematopoietic support, thus limiting the benefits of using
IFN-g-stimulated BM-MSCs in BM transplantation settings.
The findings of this study may also contribute to the un-
derstanding of the underlying causes of AAA. Several stud-
ies showed defective proliferation and differentiation of BM-
MSCs from AAA patients [51–53], which are known to have
increased levels of circulating IFN-g [54]. One study demon-
strated reduced outgrowth of CD34+ HSPCs when cocultured
with AAA BM-MSCs compared with healthy stroma,
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consistent with our findings on reduced hematopoietic support
by culture-expanded BM-MSCs pretreated with IFN-g [51]. In
contrast, others have reported no functional defects in MSCs
derived from AAA patients [55]. Thus, there might be a role
for IFN-g-stimulated BM-MSCs in the pathology of AAA, but
the underlying mechanism and the extent of this effect should
be addressed by further research. In conclusion, IFN-g does not
increase hematopoietic support of BM-MSC, but rather has
negative effect on their maintenance, which is correlated with
decreased support for quiescent HSCs in vivo. This knowledge
provides an argument against the use of IFN-g priming of
MSCs for clinical therapies that aim to enhance hematopoietic
engraftment. In addition, our work offers valuable insight into
the impact of an inflammatory environment on the BM as a
supporting organ for hematopoiesis.
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FIG. 3. HS(P)C numbers and
quiescence in ARE-Del mice.
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